Acquisitions Help Drive Up Sales At Switzerland's Galenica In 2021
Executive Summary
Galenica's Swiss consumer health business Verfora saw sales jump by a fifth in 2021 thanks to key acquisitions. Without the impact of these deals, Verfora's sales over the 12 months would have declined due to the negative impact of the pandemic on its business.
You may also be interested in...
Boiron Partners With Galenica's Verfora In Switzerland
France's Boiron has granted Galenica's Verfora the rights to distribute in Switzerland its portfolio of over 800 products as it looks to turnaround its business and make cost savings following the collapse of homeopathy sales in its home market.
EU Business Round-Up: Galenica Acquires Spagyros, Karo Offloads OTCs, And Ceres Gets New Owners
The latest European business news: Galenica strengthens its porfolio in Switzerland with Spagyros; Sweden's Karo offloads OTCs to Evolan; and Ceres Pharma sold to French private-equity firm.
Galenica Grows In Switzerland With Dr. Wild OTC Portfolio
Galenica has acquired an OTC portfolio from Switzerland's Dr. Wild, led by the market leading vitamin D supplements Vitamin D3 Wild Oil and VI-DE 3, which generated sales of CHF19m in 2020.